Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2008

View Archived Issues

BMD increased by percutaneous injection of novel GEM-OS2 in preclinical studies

Bone formation enhanced with GSK's calcium-sensing receptor antagonist ronacaleret

New agents for diabetic nephropathy disclosed in recent Kowa patent

Recent Wyeth patent reports novel bazedoxifene prodrugs

AEterna completes enrollment in phase III study of LHRH antagonist cetrorelix in BPH

Boehringer and Evec sign license agreement for fully human therapeutic antibody program

Athera and Dyax sign collaboration agreement for antibodies in cardiovascular inflammation

Calabar initiates phase II study of Xalieve in xerostomia

AEterna initiates second stage of patient recruitment in phase II ovarian cancer trial of AEZS-108

Novel agents for cardiovascular disorders described in recent patent literature

deCODE files IND for DG-071 for Alzheimer's disease and other cognitive disorders

Genentech, Roche and Glycart sign development agreement for monoclonal antibody GA-101

Genentech reports case of PML in patient who received Raptiva for more than 4 years

Crucell receives contract from NIAID to advance Ebola and Marburg vaccines

DSMB recommends continuation of BioMS Medical's MAESTRO-03 trial of dirucotide in MS

Lilly and Deciphera sign agreement for B-Raf kinase inhibitors for cancer treatments

Astellas launches Irribow in Japan for diarrhea-predominant IBS

CombinatoRx reports top-line results from phase IIb Synavive study

Dendreon presents interim data from phase III Provenge trial

PDC Biotech reports progress on preclinical program for PDC-31

Rifaximin achieves significant results in prevention of hepatic encephalopathy

Unigene initiates phase I study for oral PTH

Lilly to acquire ImClone Systems

R&D highlights from the UBS Global Life Sciences Conference in New York: Vectura Group

Novel pharmacological chaperones identified as promising agents to treat phenylketonuria

Adjuvant therapy with catumaxomab safe in phase II gastric cancer study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...